Simultaneous detrection of multiple cytokines in ELISPOT assays.
Palzer S. Bailey T., Hartnett C., Grant A., Tsang M., Kalyuzhny AE.
Methods Mol Biol. 2005; 305:273-88  2005

ELISPOT AssaysThe Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity
Kimberly Shafer-Weaver, Thomas Sayers, Susan Strobl, Eric Derby, Tracy Ulderich, Michael Baseler and Anatoli Malyguine
Journal of Translational Medicine 2003, 1:14     doi:10.1186/1479-5876-1-14  2003

ELISPOT AssaysProtein kinase C [beta]II activation induces angiotensin converting enzyme expression in neonatal rat cardiomyocytes.
Yuke Zhang, Laura J. Bloem, Lan Yu, Thomas B. Estridge, Philip W. Iversen, Christine E. McDonald, James P. Schrementi, XuShan Wang, Chris J. Vlahos and Jian Wang
Cardiovascular Research 57 (1): 139-146  2003

Enzyme AssaysRegional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity.
Hongxun Sang, Vladimir M. Pisarev, Corey Munger, Simon Robinson, Jennifer Chavez, Lori Hatcher, Prahlad Parajuli, Yajun Guo and James E. Talmadge
Vaccine 21 (21-22): 3019-3029  2003

ELISPOT AssaysCD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice.
Jennifer L. Harcourt, Michael P. Brown, Larry J. Anderson and Ralph A. Tripp
Vaccine 21 (21-22): 2964-2979  2003

ELISPOT AssaysRectal immunization of mice with hepatitis A vaccine induces stronger systemic and local immune responses than parenteral immunization.
Leslie Ann Mitchell and Eithan Galun
Vaccine 21 (13-14): 1527-1538  2003

ELISPOT AssaysA novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design.
Roshni Sundaram, Yiping Sun, Christopher M. Walker, Francois A. Lemonnier, Steven Jacobson and Pravin T. P. Kaumaya
Vaccine 21 (21-22): 2767-2781  2003

ELISPOT AssaysEffective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
Wai Ming Li, Wieslawa H. Dragowska, Marcel B. Bally and Marie-Paule Schutze-Redelmeier
Vaccine 21 (23): 3319-3329  2003

ELISPOT AssaysThe role of lipopolysaccharide in T-cell responses following DNA vaccination.
William G. Hawkins, Jiri Trcka, Neil Segal, Nathalie E. Blachere, Jason S. Gold, Yoichi Moroi, Wilbur B. Bowne, Jonathan J. Lewis, Jedd D. Wolchok and Alan N. Houghton
Vaccine 21 (13-14): 1548-1553  2003

ELISPOT AssaysA quantitive, highly sensitive cell-based infectivity assay for mouse scrapie prions.
P.-C. Klöhn, L. Stoltze, E. Flechsig, M. Enari, and C. Weissmann
PNAS 100 (D6920): 11666-11671  2003

ELISPOT AssaysCpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum.
Yan Zhang, Guy H. Palmer, Jeffrey R. Abbott, Chris J. Howard, Jayne C. Hope and Wendy C. Brown
Vaccine 21 (23): 3307-3318  2003

ELISPOT AssaysPolyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice.
Lena Degling Wikingsson and Ingvar Sjoholm
Vaccine 20 (27-28): 3355-3363  2002

ELISPOT AssaysUnique therapeutic effects of the Japanese-Chinese herbal medicine, Sairei-to, on Th1/Th2 cytokines balance of the autoimmunity of MRL/lpr mice.
Taisuke Ito, Naohiro Seo, Hiroaki Yagi, Toshio Ohtani, Yoshiki Tokura, Masahiro Takigawa and Fukumi Furukawa
Journal of Dermatological Science 28 (3): 198-210  2002

ELISPOT AssaysEnhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15--the Amplispot assay.
Wim Jennes, Luc Kestens, Douglas F. Nixon and Barbara L. Shacklett
Journal of Immunological Methods 270 (1): 99-108  2002

ELISPOT AssaysIncreased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors
Hollo K,Ann Rheum Dis. Feb;60(2):133-9.
Ann Rheum Dis. Feb;60(2):133-9.  2001

ELISPOT AssaysSurrogate markers of antitumor responses: in vitro activation of T cells by autologous tumor peptides.
Zier K, et al.; Clin Cancer Res. 2001 Mar;7(3 Suppl):818s-821s.
Clin Cancer Res. 2001 Mar;7(3 Suppl):818s-821s.  2001

ELISPOT AssaysLocoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
Manzke O, et al.,Int J Cancer. 2001 Feb 15;91(4):516-22
Int J Cancer. 2001 Feb 15;91(4):516-22  2001

ELISPOT AssaysFailure to detect HLA-A*6802-restricted CD8+ T cells specific for Chlamydia trachomatis antigens in subjects from trachoma-endemic communities
Mahdi OS,Clin Exp Immunol. 2001 Jan;123(1):68-72.
Clin Exp Immunol. 2001 Jan;123(1):68-72.  2001

ELISPOT AssaysA disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin
Alleva DG, et al.,J Clin Invest. 2001 Jan;107(2):173-80.
J Clin Invest. 2001 Jan;107(2):173-80.  2001

ELISPOT AssaysElispot analysis of hepatitis c virus protein-specific ifn-gamma-producing peripheral blood lymphocytes in infected humans with and without cirrhosis
Anthony DD, et al.,Clin Immunol. 2001 May;99(2):212-20.
Clin Immunol. 2001 May;99(2):212-20.  2001

ELISPOT AssaysCharacterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes
Sarobe P, et al, J Hepatol. 2001 Feb;34(2):321-9.
J Hepatol. 2001 Feb;34(2):321-9.  2001

ELISPOT AssaysHepatitis c virus-specific cd4+ t cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease
Schirren CA, et al.,J Infect Dis. 2001 Apr 15;183(8):1187-94.
J Infect Dis. 2001 Apr 15;183(8):1187-94.  2001

ELISPOT AssaysOligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients
Schrama D,Cancer Res. 2001 Jan 15;61(2):493-6.
Cancer Res. 2001 Jan 15;61(2):493-6.  2001

ELISPOT AssaysTreatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells.
Farina C, et al. ,Brain. 2001 Apr;124(Pt 4):705-19.
Brain. 2001 Apr;124(Pt 4):705-19.  2001

ELISPOT AssaysT-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls
Hellings N, et al,J Neurosci Res. 2001 Feb 1;63(3):290-302.
J Neurosci Res. 2001 Feb 1;63(3):290-302.  2001

ELISPOT AssaysMonocytes in multiple sclerosis: phenotype and cytokine profile
Kouwenhoven M,,J Neuroimmunol. 2001 Jan 1;112(1-2):197-205.
J Neuroimmunol. 2001 Jan 1;112(1-2):197-205.  2001

ELISPOT AssaysA murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy
Small LA, et al.,Clin Cancer Res. 2001 Mar;7(3 Suppl):876s-881s.
Clin Cancer Res. 2001 Mar;7(3 Suppl):876s-881s.  2001

ELISPOT AssaysNatural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes
van der Burg SH, et al.
Int J Cancer. 2001 Mar 1;91(5):612-8.  2001

ELISPOT AssaysHPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination
Kaufmann AM, et al.,Int J Cancer. 2001 Apr 15;92(2):285-93.
Int J Cancer. 2001 Apr 15;92(2):285-93.  2001

ELISPOT AssaysActivation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine
Wuorimaa T, et al.,Scand J Immunol. 2001 Apr;53(4):422-8.
Scand J Immunol. 2001 Apr;53(4):422-8.  2001

ELISPOT AssaysEarly commitment of adoptively transferred CD4+ T cells following particle-mediated DNA vaccination: implications for the study of immunomodulation
Creusot RJ, et al,Vaccine. 2001 Feb 8;19(13-14):1678-87.
Vaccine. 2001 Feb 8;19(13-14):1678-87.  2001

ELISPOT AssaysExpansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide.
Pittet MJ, et al.,Clin Cancer Res. 2001 Mar;7(3 Suppl):796s-803s.
Clin Cancer Res. 2001 Mar;7(3 Suppl):796s-803s.  2001

ELISPOT AssaysCD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing
Allen TM, et al.,J Virol. 2001 Jan;75(2):738-49.
J Virol. 2001 Jan;75(2):738-49.  2001

ELISPOT AssaysMicrosphere translocation and immunopotentiation in systemic tissues following intranasal administration.
J. E. Eyles, V. W. Bramwell, E. D. Williamson and H. O. Alpar
Vaccine 19 (32): 4732-4742  2001

ELISPOT AssaysAllergy
Gabrielsson S, et al.; Allergy. Apr; 56(4):293-300
Allergy. Apr; 56(4):293-300  2001

ELISPOT AssaysIL-12 elispot assays to detect and enumerate IL-12 secreting cells
Ozenci V.; Kouwenhoven M.; Press R.; Link H.; Huang Y.-M.
Cytokine SO- 12/8 (1218-1224) 2000  2000

Enzyme AssaysCharacterization of the cytokine network at a single cell level in mice with collagen-induced arthritis using a dual color ELISPOT assay.
Okamoto Y, et al. ,J Interferon Cytokine Res. 2000 Jan;20(1):55-61.
J Interferon Cytokine Res. 2000 Jan;20(1):55-61.  2000

ELISPOT AssaysImmunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study
Janetzki S, et al; Int J Cancer. 2000 Oct 15;88(2):232-8.
Int J Cancer. 2000 Oct 15;88(2):232-8.  2000

ELISPOT AssaysEvaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines
Asai T, et al,Clin Diagn Lab Immunol. 2000 Mar;7(2):145-54
Clin Diagn Lab Immunol. 2000 Mar;7(2):145-54  2000

ELISPOT AssaysAutoimmunity in ulcerative colitis (UC): a predominant colonic mucosal B cell response against human tropomyosin isoform 5
Onuma EK, et al,Clin Exp Immunol. 2000 Sep;121(3):466-71.
Clin Exp Immunol. 2000 Sep;121(3):466-71.  2000

ELISPOT AssaysTh1-like dominance in high-risk first-degree relatives of type I diabetic patients
Karlsson MG,Diabetologia. 2000 Jun;43(6):742-9.
Diabetologia. 2000 Jun;43(6):742-9.  2000

ELISPOT AssaysApplication of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens
Yang J, et al.,Blood. 2000 Jan 1;95(1):241-8.
Blood. 2000 Jan 1;95(1):241-8.  2000

ELISPOT AssaysAnalysis of successful immune responses in persons infected with hepatitis C virus
Lechner F, et al; J Exp Med. 2000 May 1;191(9):1499-512.
J Exp Med. 2000 May 1;191(9):1499-512.  2000

ELISPOT AssaysCellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.
Rahman F, et al,Hepatology. 2000 Feb;31(2):521-7.
Hepatology. 2000 Feb;31(2):521-7.  2000

ELISPOT AssaysImmune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients.
Valdez H, et al., AIDS. 2000 Oct 20;14(15):2239-46.
AIDS. 2000 Oct 20;14(15):2239-46.  2000

ELISPOT AssaysInduction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma
Dale CJ, et al,J Med Primatol. 2000 Aug;29(3-4):240-7.
J Med Primatol. 2000 Aug;29(3-4):240-7.  2000

ELISPOT AssaysQuantitation of virus-specific classes of antibodies following immunization of mice with attenuated equine herpesvirus 1 and viral glycoprotein D.
Zhang Y, et al.,Virology. 2000 Mar 15;268(2):482-92.
Virology. 2000 Mar 15;268(2):482-92.  2000

ELISPOT AssaysAssessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy.
Keane NM, Price P, Stone SF, John M, Murray RJ, French MA
AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):1991-6.  2000

ELISPOT AssaysHIV-Specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA
Moss RB, et al,J Interferon Cytokine Res. 2000 Dec;20(12):1131-7.
J Interferon Cytokine Res. 2000 Dec;20(12):1131-7.  2000

ELISPOT AssaysFunctionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children.
Goulder PJ, et al,J Exp Med. 2000 Dec 18;192(12):1819-32.
J Exp Med. 2000 Dec 18;192(12):1819-32.  2000

ELISPOT AssaysEndocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation
Andrieu M, et al.,Eur J Immunol. 2000 Nov;30(11):3256-65.
Eur J Immunol. 2000 Nov;30(11):3256-65.  2000

ELISPOT AssaysT-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV
Clerici M, et al,Blood. 2000 Dec 1;96(12):3866-71.
Blood. 2000 Dec 1;96(12):3866-71.  2000

ELISPOT AssaysQuantification of HIV-1-specific T-cell responses at the mucosal cervicovaginal surface.
Shacklett BL, et al.; AIDS. 2000 Sep 8;14(13):1911-5.
AIDS. 2000 Sep 8;14(13):1911-5.  2000

ELISPOT AssaysHIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant
Moss RB,J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):264-9.
J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):264-9.  2000

ELISPOT AssaysRapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry
Moretto WJ, et al,AIDS. 2000 Nov 10;14(16):2625-7.
AIDS. 2000 Nov 10;14(16):2625-7.  2000

ELISPOT AssaysCD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia
Wierda WG, et al; Blood. 2000 Nov 1;96(9):2917-24.
Blood. 2000 Nov 1;96(9):2917-24.  2000

ELISPOT AssaysHLA-A*0201 restricted CD8+ T-lymphocyte responses to malaria: identification of new Plasmodium falciparum epitopes by IFN-gamma ELISPOT
Gonzalez JM, et al.
Parasite Immunol. 2000 Oct;22(10):501-14.  2000

ELISPOT AssaysGeneration and characterization of malaria-specific human CD8(+) lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentationby liver cells
Bonelo A, et al,Eur J Immunol. 2000 Nov;30(11):3079-88.
Eur J Immunol. 2000 Nov;30(11):3079-88.  2000

ELISPOT AssaysA novel sensitive approach for frequency analysis of measles virus-specific memory T-lymphocytes in healthy adults with a childhood history of natural measles
Nanan R, et al.,J Gen Virol. 2000 May;81 Pt 5:1313-9.
J Gen Virol. 2000 May;81 Pt 5:1313-9.  2000

ELISPOT AssaysSelective in vivo suppression of T lymphocyte responses in experimental measles virus infection
Niewiesk S, et al.,Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4251-5.
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4251-5.  2000

ELISPOT AssaysAnalysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations
Yamshchikov G, et al.
Clin Cancer Res. 2001:909s-916s.  2000

ELISPOT AssaysIdentification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
Reynolds SR, Celis E, et al.
J Immunol Methods. 2000 Oct 20;244(1-2):59-67.  2000

ELISPOT AssaysIdentification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
Jager E, et al. ,J Exp Med. 2000 Feb 21;191(4):625-30.
J Exp Med. 2000 Feb 21;191(4):625-30.  2000

ELISPOT AssaysMelanoma vaccines: the paradox of T cell activation without clinical response
Nielsen MB, et al. ,Cancer Chemother Pharmacol. 2000;46 Suppl:S62-6.
Cancer Chemother Pharmacol. 2000;46 Suppl:S62-6.  2000

ELISPOT AssaysPaucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients
Dhodapkar MV, et al; Clin Cancer Res. 2000 Dec;6(12):4831-8.
Clin Cancer Res. 2000 Dec;6(12):4831-8.  2000

ELISPOT AssaysInduction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies
Chang JW,Anticancer Res. 2000 May-Jun;20(3A):1329-36.
Anticancer Res. 2000 May-Jun;20(3A):1329-36.  2000

ELISPOT AssaysHigh frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma
Letsch A, ,Int J Cancer. 2000 Sep 1;87(5):659-64.
Int J Cancer. 2000 Sep 1;87(5):659-64.  2000

ELISPOT AssaysEvaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
Lewis JJ, Janetzki S
Int J Cancer. 2000 Aug 1;87(3):391-8.  2000

ELISPOT AssaysPhase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma
Scheibenbogen C,J Immunother. 2000 Mar-Apr;23(2):275-81.
J Immunother. 2000 Mar-Apr;23(2):275-81.  2000

ELISPOT AssaysMonitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond
Gajewski TF.et al,Clin Diagn Lab Immunol. 2000 Mar;7(2):141-4
Clin Diagn Lab Immunol. 2000 Mar;7(2):141-4  2000

ELISPOT AssaysVaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects
Titzer S, et al; Br J Haematol. 2000 Mar;108(4):805-16.
Br J Haematol. 2000 Mar;108(4):805-16.  2000

ELISPOT AssaysSpontaneous monoclonal immunoglobulin-secreting peripheral blood mononuclear cells as a marker of disease severity in multiple myeloma
Cordoba F, et al,Br J Haematol. 2000 Mar;108(3):549-58.
Br J Haematol. 2000 Mar;108(3):549-58.  2000

ELISPOT AssaysPeripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring.
Openshaw H, et al,Biol Blood Marrow Transplant. 2000;6(5A):563-75.
Biol Blood Marrow Transplant. 2000;6(5A):563-75.  2000

ELISPOT AssaysQuantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production
Pelfrey CM,et al.,J Immunol. 2000 Aug 1;165(3):1641-51.
J Immunol. 2000 Aug 1;165(3):1641-51.  2000

ELISPOT AssaysMultiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment
Ozenci V,Clin Exp Immunol. 2000 Apr;120(1):147-53.
Clin Exp Immunol. 2000 Apr;120(1):147-53.  2000

ELISPOT AssaysKinetics of circulating antibodies, immune complex and specific antibody-secreting cells in tuberculosis patients during 6 months of antimicrobial therapy
Sousa AO, et al; Tuber Lung Dis. 2000;80(1):27-33.
Tuber Lung Dis. 2000;80(1):27-33.  2000

ELISPOT AssaysCarbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens
Bacon A, et al,Infect Immun. 2000 Oct;68(10):5764-70.
Infect Immun. 2000 Oct;68(10):5764-70.  2000

ELISPOT AssaysMature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses
Herr W, et al.,Blood. 2000 Sep 1;96(5):1857-64.
Blood. 2000 Sep 1;96(5):1857-64.  2000

ELISPOT AssaysAllogeneic vaccination for renal cell carcinoma: development and monitoring
Pohla H, et al.,Bone Marrow Transplant. 2000 May;25 Suppl 2:S83-7.
Bone Marrow Transplant. 2000 May;25 Suppl 2:S83-7.  2000

ELISPOT AssaysPilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
von Mehren M,Clin Cancer Res. 2000 Jun;6(6):2219-28.
Clin Cancer Res. 2000 Jun;6(6):2219-28.  2000

ELISPOT Assays4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination
Tan JT; J Immunol. 2000 Mar 1;164(5):2320-5.
J Immunol. 2000 Mar 1;164(5):2320-5.  2000

ELISPOT AssaysGeneration of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
Meidenbauer N, et al.
Prostate. 2000 May 1;43(2):88-100.  2000

ELISPOT AssaysThe use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines
Arlen P, et al. ,Cancer Immunol Immunother. 2000 Dec;49(10):517-29.
Cancer Immunol Immunother. 2000 Dec;49(10):517-29.  2000

ELISPOT AssaysPresentation of SIVgag to monkey T cells using dendritic cells transfected with a recombinant adenovirus
Zhong L, et al,Eur J Immunol. 2000 Nov;30(11):3281-90.
Eur J Immunol. 2000 Nov;30(11):3281-90.  2000

ELISPOT AssaysSpecificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes
Tan LC, et al,Arthritis Res. 2000;2(2):154-64.
Arthritis Res. 2000;2(2):154-64.  2000

ELISPOT AssaysInduction of B-cell tolerance by retroviral gene therapy
Bracy JL, et al.; Blood. 2000 Nov 1;96(9):3008-15.
Blood. 2000 Nov 1;96(9):3008-15.  2000

ELISPOT AssaysCirculating rotavirus-specific antibody-secreting cells (ASCs) predict the presence of rotavirus-specific ASCs in the human small intestinal lamina propria
Brown KA, et al. , J Infect Dis. 2000 Oct;182(4):1039-43.
J Infect Dis. 2000 Oct;182(4):1039-43.  2000

ELISPOT AssaysPhase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
Horig H, et al.,Cancer Immunol Immunother. 2000 Nov;49(9):504-14.
Cancer Immunol Immunother. 2000 Nov;49(9):504-14.  2000

ELISPOT AssaysSystemic and mucosal immune responses to H1N1 influenza virus infection in pigs
Larsen DL, et al.; Vet Microbiol. 2000 May 22;74(1-2):117-31.
Vet Microbiol. 2000 May 22;74(1-2):117-31.  2000

ELISPOT AssaysImmunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus.
Oliveira-Ferreira J,Vaccine. 2000 Mar 6;18(17):1863-9.
Vaccine. 2000 Mar 6;18(17):1863-9.  2000

ELISPOT AssaysAntibody-dependent induction of type I interferons by poliovirus in human mononuclear blood cells requires the type II fcgamma receptor (CD32)
Palmer P, et al. ,Virology. 2000 Dec 5;278(1):86-94.
Virology. 2000 Dec 5;278(1):86-94.  2000

ELISPOT AssaysImmunoblotting, dot-blotting, and ELISPOT assays: methods and applications
Stott DI. et al.,J Immunoassay. 2000 May-Aug;21(2-3):273-96. Review.
J Immunoassay. 2000 May-Aug;21(2-3):273-96. Review.  2000

ELISPOT AssaysPristane-induced arthritis in mice selected for maximal or minimal acute inflammatory reaction.
,Eur J Immunol. Feb;30(2):431-7.
Eur J Immunol. Feb;30(2):431-7.  2000

ELISPOT Assays